Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07198347
PHASE3

Efficacy and Safety of AG2001 in Patients With Acute Bronchitis

Sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd

View on ClinicalTrials.gov

Summary

This is a Phase 3, randomized, double-blind, active-controlled clinical trial designed to evaluate the efficacy and safety of AG2001 in patients with acute bronchitis. The primary objective is to demonstrate the superiority of AG2001 over two active comparators based on the change in Bronchitis Severity Score (BSS) at Day 4.

Official title: A Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2001 in Patients With Acute Bronchitis

Key Details

Gender

All

Age Range

19 Years - 64 Years

Study Type

INTERVENTIONAL

Enrollment

300

Start Date

2025-11-01

Completion Date

2026-10-31

Last Updated

2025-09-30

Healthy Volunteers

No

Interventions

DRUG

AG2001

Oral administration, three times daily for 7 days.

DRUG

AG20011

Oral administration, three times daily for 7 days.

DRUG

AG20012

Oral administration, three times daily for 7 days.